SecBot SecBot
PRESS-RELEASE ·Filed Mar 24, 2026

MDAI

Spectral AI, Inc.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor FDA decision on De Novo 510(k) submission for DeepView System — commercialization remains key to future revenue. Despite improved cash and reduced losses, declining R&D revenue and lack of near-term product sales limit bullishness. Warrant liability volatility could distort future earnings.

DirectionMixed
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
MDAI ▲ +14.15% at T+60d
NEUTRAL call +14.15% · α vs SPY +0.69% · entry $1.54 → $1.76
Entry = T+0 close
Mar 24, 2026
via day close
T+1d
-1.30%
call -1.30% · α +0.47%
$1.52
settled 7mo ago
T+5d
-6.49%
call -6.49% · α -6.25%
$1.44
settled 7mo ago
T+20d
+16.88%
call +16.88% · α +9.02%
$1.80
settled 6mo ago
T+60d
+14.15%
call +14.15% · α +0.69%
$1.76
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Spectral AI reported FY 2025 revenue of $19.7 million, down 33.5% YoY, with Q4 revenue halving to $3.8 million due to reduced BARDA-related reimbursed costs. Despite declining core revenue, the company swung to a Q4 net profit of $0.6 million (vs. $7.7M loss) due to a $4.0M non-cash gain on warrant liability, while cash surged to $15.4 million from financings and warrant exercises.

Key Financial Metrics

Revenue
$19.7M
-33.5% YoY
EPS
$0.02
Guidance
$18.5M
initiated

Key Facts

  • FY 2025 revenue declined to $19.7M from $29.6M in FY 2024 (-33.5%)
  • Q4 2025 revenue was $3.8M, down from $7.6M in Q4 2024 (-50%)
  • Q4 net income was $0.6M (EPS $0.02) vs. $7.7M loss ($-0.41) due to $4.0M gain on warrant liability
  • Full-year net loss narrowed to $7.6M from $15.3M in 2024
  • Cash increased to $15.4M from $5.2M at year-end 2024
  • 2026 revenue guidance set at $18.5M, excluding commercial sales of DeepView System
  • Received $31.7M in non-dilutive BARDA funding; total BARDA contract value up to $150M

Financial Impact

Revenue down $9.9M YoY; net loss improved by $7.7M due to non-recurring gains and lower expenses

revenueepscashoperating_losswarrant_liability

Risk Factors

  • Revenue is heavily dependent on BARDA funding and lacks commercial product sales
  • Net income driven by non-recurring fair value gains, not core operations
  • High warrant liability ($11.5M) creates earnings volatility
  • 2026 guidance excludes commercial revenue, indicating prolonged pre-revenue phase

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3261781
5 reports for MDAI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MDAI — sortable, filterable
TypeNow
Aug 12, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$1.73awaiting T+60—$1.50 (−13.58%)
Jul 8, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$1.72 $1.66▼ −3.49%▼ −5.12%$1.50 (−13.08%)
Mar 24, 2026
30w ago
Press Release
MIXED ★ 6/10
$1.54 $1.76▲ +14.15%▲ +0.69%$1.50 (−2.92%)
Mar 18, 2026
31w ago
Press Release
BULLISH ★ 8/10
$1.42 $1.84▲ +29.58%▲ +15.23%$1.50 (+5.28%)
Mar 10, 2026
32w ago
Press Release
NEUTRAL ★ 3/10
$1.40 $1.94▲ +38.57%▲ +26.89%$1.50 (+6.79%)
Showing 5 of 5

US Market Status

Market Open — Closes in 3h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 24, 2026